Cytokine and chemokine dysregulation in hyper-IgE syndrome

被引:48
作者
Chehimi, J [1 ]
Elder, M
Greene, J
Noroski, L
Stiehm, ER
Winkelstein, JA
Sullivan, KE
机构
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Johns Hopkins Sch Med, Baltimore, MD 21287 USA
[3] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90095 USA
[4] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA
[5] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA
关键词
IL-12; ENA78; MCP-3; eotaxin; chemokines; hyper-IgE; Job's syndrome;
D O I
10.1006/clim.2001.5039
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hyper-IgE syndrome is characterized by severe recurrent staphylococcal infections, eczema, boney abnormalities, and markedly elevated levels of immunoglobulin E (IgE). The genetic basis is not known and the central immunologic defect is largely undefined. Reduced neutrophil chemotaxis is often described, and variable T cell defects have been demonstrated in some patients. It has been hypothesized that hyper-IgE is associated with a Th1/Th2 imbalance. We wished to characterize cytokine and chemokine imbalances that might reflect the underlying disease process or reflect ongoing pathologic processes. Nine patients with hyper-IgE syndrome and six controls were studied. Radioimmunoassays, flow cytometry, and gene array analyses were performed to characterize cytokine and chemokine production. Hyper-IgE patients express more IL-12, while ENA-78, MCP-3, and eotaxin are markedly underexpressed. Underexpression of a set of chemokines could explain a number of features of hyper-IgE syndrome and may offer a new paradigm for the understanding of this disorder. (C) 2001 Academic Press.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 38 条
[1]   Recombinant IFN-γ treatment of a patient with hyperimmunoglobulin E syndrome triggered autoimmune thrombocytopenia [J].
Aihara, Y ;
Mori, M ;
Katakura, S ;
Yokota, S .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1998, 18 (08) :561-563
[2]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[3]   Defective interleukin-12/interferon-γ pathway in patients with hyperimmunoglobulinemia E syndrome [J].
Borges, WG ;
Augustine, NH ;
Hill, HR .
JOURNAL OF PEDIATRICS, 2000, 136 (02) :176-180
[4]   Selective suppression of IL-12 production by chemoattractants [J].
Braun, MC ;
Lahey, E ;
Kelsall, BL .
JOURNAL OF IMMUNOLOGY, 2000, 164 (06) :3009-3017
[5]  
BUCKLEY RH, 1972, PEDIATRICS, V49, P59
[6]  
BUNDICK RV, 1995, CLIN EXP IMMUNOL, V99, P467
[7]   ENHANCING EFFECT OF NATURAL-KILLER-CELL STIMULATORY FACTOR (NKSF/INTERLEUKIN-12) ON CELL-MEDIATED CYTOTOXICITY AGAINST TUMOR-DERIVED AND VIRUS-INFECTED CELLS [J].
CHEHIMI, J ;
VALIANTE, NM ;
DANDREA, A ;
RENGARAJU, M ;
ROSADO, Z ;
KOBAYASHI, M ;
PERUSSIA, B ;
WOLF, SF ;
STARR, SE ;
TRINCHIERI, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (08) :1826-1830
[8]   Differential production of interleukin 10 during human immunodeficiency virus infection [J].
Chehimi, J ;
Ma, XJ ;
Chouaib, S ;
Zyad, A ;
Nagashunmugam, T ;
Wojcik, L ;
Chehimi, S ;
Nissim, L ;
Frank, I .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (12) :1141-1149
[9]   IMPAIRED INTERLEUKIN-12 PRODUCTION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS [J].
CHEHIMI, J ;
STARR, SE ;
FRANK, I ;
DANDREA, A ;
MA, XJ ;
MACGREGOR, RR ;
SENNELIER, J ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (04) :1361-1366
[10]   Type 1 and type 2 cytokines in HIV infection - A possible role in apoptosis and disease progression [J].
Clerici, M ;
Fusi, ML ;
Ruzzante, S ;
Piconi, S ;
Biasin, M ;
Arienti, D ;
Trabattoni, D ;
Villa, ML .
ANNALS OF MEDICINE, 1997, 29 (03) :185-188